Loading clinical trials...

A Study of PSB205 in Subjects With Advanced Solid Tumors | Clinical Trials | Clareo Health

UNKNOWNPHASE1

A Study of PSB205 in Subjects With Advanced Solid Tumors

A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients With Relapsed/Refractory Solid Tumors

NCT03986606•Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

View on ClinicalTrials.gov

Summary

This is an open-label, multicenter, Phase 1, ascending dose escalation study of PSB205 in subjects with advanced solid tumors. The study will be conducted in 2 parts. Part 1 of the study will be a dose escalation evaluation to determine the maximum tolerated dose (MTD) and to establish a recommended Phase 2 dose (RP2D) of PSB205. This study purpose is to describe the safety and tolerability, to assess Pharmacokinetics (PK) and immunogenicity, and to preliminarily assess the anti-tumor activity of PSB205 in subjects with solid tumors. Part 2 of the study will further evaluate the RP2D in 3 distinct tumor cohorts of approximately 12 subjects each.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female subjects aged 18 years or older.
•Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Inclusion of subjects with an ECOG performance status of 2 should be discussed and is at the discretion of the sponsor's medical monitor and the investigator.
•Life expectancy of ≥3 months.
•Female subjects who are not pregnant or breastfeeding, 1 year postmenopausal, or surgically sterile and males even if surgically sterilized that Agree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject.
•Suitable venous access for the study-required blood sampling, including PK and Pharmacodynamic sampling.
•1. To be enrolled in Part 1 (Dose escalation), subjects must have:
•1. Histologically confirmed diagnosis of advanced solid tumor and preferably radiographically or clinically measurable disease. Subjects with non-measurable, evaluable disease are permitted
•2. One or more prior lines of therapy . No curative options and progressed on or following standard of care therapy (SOC).
•2. To be enrolled in Part 2 (Dose expansion), subjects must have:
•1. Histologically confirmed diagnosis of advanced solid tumor of the following types, and radiographically or clinically measurable disease, one or more prior lines of therapy, no curative options and progressed on or following SOC.
+7 more criteria

Exclusion Criteria

•1. Active or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegener syndrome) within the past 2 years. Subjects with childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
•2. Grade 3 or Grade 4 irAEs related to prior cancer immunotherapy.
•3. Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression. Subjects previously treated central nervous system metastases that are radiographically and neurologically stable for at least 6 weeks and do not require corticosteroids (of any dose) for symptomatic management for at least 14 days prior to first dose of study drug are permitted to enroll.
•4. Hypertension unable to be controlled to ≤Grade 2 with medication.
•5. Any condition requiring systemic treatment with corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before first dose of study drug. Corticosteroids for topical use, nasal spray, and inhaled steroids are allowed. Systemic corticosteroids for prophylaxis of contrast allergy are permitted.
•6. Prior treatment with a CTLA-4 inhibitor in combination with a PD-1 or PD-L1 inhibitor.
•7. Systemic anti-cancer treatment (including investigational agents). This includes radiotherapy \<2 weeks before the first dose of study drug, ≤4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T cell engaging agents; (≤8 weeks for cell-based therapy or anti-tumor vaccine) or have not recovered from acute toxic effects from prior chemotherapy and radiotherapy.
•8. Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
•9. Systemic infection requiring IV antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
•10. Subjects with a history of organ transplant.
+9 more criteria

Locations (1)

Next Oncology

San Antonio, Texas, United States

Key Dates

Start Date

July 5, 2019

Primary Completion Date

February 28, 2021

Completion Date

July 28, 2021

Last Updated

November 25, 2020

Enrollment

ESTIMATED participants

Conditions

Neoplasm Malignant

Interventions

PSB205

BIOLOGICAL

Contacts

Cynthia Erdman

CONTACT

1-913-410-2815 ErdmanCynthia@prahs.com

Jelle Kijilstra, M.D, MPH

CONTACT

1-425-398-2323 Jelle@soundbiologics.com

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT07209111

Neoplasm Malignant

View study

RECRUITINGNA

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

NCT06310330

Breast Neoplasm Malignant Primary

View study

RECRUITINGPHASE2

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

NCT05247268

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 25, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of PSB205 in Subjects With Advanced Solid Tumors

Inclusion Criteria

Exclusion Criteria

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Study of the Impact of DPD Activity on the Efficacy of Capecitabine

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)